These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Ganglion cell loss in early glaucoma, as assessed by photopic negative response, pattern electroretinogram, and spectral-domain optical coherence tomography. Cvenkel B; Sustar M; Perovšek D Doc Ophthalmol; 2017 Aug; 135(1):17-28. PubMed ID: 28567618 [TBL] [Abstract][Full Text] [Related]
4. Association of Preclinical Alzheimer Disease With Optical Coherence Tomographic Angiography Findings. O'Bryhim BE; Apte RS; Kung N; Coble D; Van Stavern GP JAMA Ophthalmol; 2018 Nov; 136(11):1242-1248. PubMed ID: 30352114 [TBL] [Abstract][Full Text] [Related]
5. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets. Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL; Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169 [TBL] [Abstract][Full Text] [Related]
6. Comparing three different modes of electroretinography in experimental glaucoma: diagnostic performance and correlation to structure. Wilsey L; Gowrisankaran S; Cull G; Hardin C; Burgoyne CF; Fortune B Doc Ophthalmol; 2017 Apr; 134(2):111-128. PubMed ID: 28243926 [TBL] [Abstract][Full Text] [Related]
7. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model. Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W; J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262 [TBL] [Abstract][Full Text] [Related]
8. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study. Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097 [TBL] [Abstract][Full Text] [Related]
11. Alzheimer's Disease Biomarkers and Future Decline in Cognitive Normal Older Adults. Dumurgier J; Hanseeuw BJ; Hatling FB; Judge KA; Schultz AP; Chhatwal JP; Blacker D; Sperling RA; Johnson KA; Hyman BT; Gómez-Isla T J Alzheimers Dis; 2017; 60(4):1451-1459. PubMed ID: 29036824 [TBL] [Abstract][Full Text] [Related]
12. Self-reported traumatic brain injury and in vivo measure of AD-vulnerable cortical thickness and AD-related biomarkers in the ADNI cohort. Wang ML; Wei XE; Yu MM; Li PY; Li WB; Neurosci Lett; 2017 Aug; 655():115-120. PubMed ID: 28689050 [TBL] [Abstract][Full Text] [Related]
13. Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study. Porter T; Burnham SC; Milicic L; Savage G; Maruff P; Lim YY; Li QX; Ames D; Masters CL; Rainey-Smith S; Rowe CC; Salvado O; Groth D; Verdile G; Villemagne VL; Laws SM; J Alzheimers Dis; 2018; 66(3):1193-1211. PubMed ID: 30412495 [TBL] [Abstract][Full Text] [Related]
14. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort. Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385 [TBL] [Abstract][Full Text] [Related]
15. Social Networks and Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Pathology in Cognitively Intact Older Adults: The CABLE Study. Ma YH; Wang YY; Tan L; Xu W; Shen XN; Wang HF; Hou XH; Cao XP; Bi YL; Dong Q; Yang JL; Yu JT J Alzheimers Dis; 2021; 81(1):263-272. PubMed ID: 33749650 [TBL] [Abstract][Full Text] [Related]